Navigation Links
In the lab and clinic, VCU Massey develops a new therapy for blood cancers
Date:6/2/2011

Richmond, Va. (June 2, 2011) Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial represented the first time a proteasome inhibitor such as Bortezomib was combined with a cell cycle inhibitor such as Alvocidib to treat patients with cancer.

Proteasome inhibitors work by blocking the action of proteasomes, which are large protein complexes that help destroy proteins that are no longer needed by the cell. Cell cycle inhibitors disrupt the sequence of events that allow cells to undergo cell division and duplication. They also have the ability to block gene transcription.

The trial included 16 patients who had either indolent (non-aggressive) non-Hodgkin's lymphoma, mantle cell lymphoma or multiple myeloma. After they received the treatments over a 21-day cycle, there were two complete responses, meaning that all detectable traces of the cancer were gone, and five partial responses.

"Therapeutic responses tend to be rare in Phase I trials, but 44 percent of our patient sample responded to the therapy. Interestingly, some patients who previously had no response to Bortezomib, or progressed after Bortezomib therapy, responded to the combination," says Beata Holkova, M.D., a hematologist-oncologist at VCU Massey and co-investigator on this clinical trial. "Because of the small patient sample size, we can't draw definitive conclusions about the effectiveness of the therapy, but we were quite encouraged by the results."

The patients received Bortezomib intravenously on days 1, 4, 8 and 11 an
'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Kreativ Dental Clinic, Offering Dental Implant and Dental Services Abroad, Launches 3D Virtual Tours Online
2. VCU Massey research finds new link between inflammation and cancer
3. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
4. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
5. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
6. VCU Massey first to combine targeted agents to kill multiple myeloma cells
7. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
8. Personal Best Develops Workplace Weight Loss Program
9. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
10. UD team develops new method for producing proteins critical to medical research
11. UMass Memorial health care develops fully integrated EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Starbrite Dental has recently developed a ... Six-Month Smiles is designed to give patients the straighter, ... effective way. , Many people find the idea of ... metal braces for several years, not to mention having ... braces clean, is undesirable and upsetting. , With Dr. ...
(Date:9/22/2014)... September 22, 2014 United States ... of the federal mesh lawsuits ( http://www.meshinjurylawfirm.com/lawsuits/ ) ... been consolidated for pretrial matters, issued an order ... Pelvic Repair System Products Liability Litigation (United States ... Virginia; Case no. 2:12-md-02326)—requiring that four member cases ...
(Date:9/22/2014)... Sundays are when people both exercise more and drink ... intake and physical activity , Findings differ from past ... A new Northwestern Medicine study finds that on days ... -- they drink more alcohol, too. , This is ... daily diary approach for self-reporting physical activity and alcohol ...
(Date:9/22/2014)... Teens and young adults at risk for sexually transmitted ... risky sexual behaviors, according to new recommendations from the ... 20 million new sexually transmitted infections such as gonorrhea ... involve people between 15 and 24 years old, according ... published Sept. 22 in Annals of Internal Medicine ...
(Date:9/22/2014)... Mich. A surprising new study pulls back the ... health care: differences in payment and income between physicians ... don,t. , Contrary to perception, the research indicates, ... favor surgeons and other procedure-performing doctors. , The new ... difference in pay per minute explains why doctors who ...
Breaking Medicine News(10 mins):Health News:Starbrite Dental Introduces Six-Month Smiles 2Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:We drink more alcohol on gym days 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 2Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 3Health News:Think the system for paying US doctors is rigged to favor surgeons? Study may surprise you 4
... ... worldwide operator with both CAMTS and EURAMI accreditation and Department of Defense approval, ... Birmingham, AL (PRWEB) ... it has earned full accreditation from the European Aero-Medical Institute (EURAMI). EURAMI is ...
... Nov. 9 HUYA Bioscience International, ... announced a strategic partnership with the School of ... agreement is another in a series of collaborations ... and development institutions to enable and accelerate the ...
... women ages 18 to 68 found that lubricant use during ... ratings of pleasurable and satisfying sex. Personal lubricants ... of sexual intercourse and to reduce the risk of vaginal ... use of lubricants or associated vaginal symptoms. The ...
... The American Public Health Association (APHA) applauds the ... passed last night by the House. , "With passage ... universal coverage, supporting important insurance reforms and moving our ... sick to one that focuses on keeping people healthy," ...
... pain now can take you out of the game later, ... injuries are the talk of the NFL this season, sidelining ... Parker. , Officials at the American Podiatric Medical Association and ... take care of their feet when they play fall sports ...
... ... Through Our Inner Pharmacy" by Dr. Roberto Giraldo shows that AIDS is a result of ... can be either chemical, physical, nutritional and most of all, emotional. , ... Oakland, CA (PRWEB) November 8, 2009 -- ...
Cached Medicine News:Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 2Health News:Indiana U. at APHA: Studies about why men and women use lubricants during sex 3Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2Health News:Rx for Fall Foot Injuries 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3
(Date:9/22/2014)... Sept. 22, 2014 Arena Pharmaceuticals, Inc. (NASDAQ: ... to present a corporate overview and update at the ... 26, 2014, at 11:30 a.m. Eastern Time (8:30 a.m. ... New York City . A ... under the investor relations section of Arena,s website at ...
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... ANGELES , Sept. 22, 2014 CytRx ... and development company specializing in oncology, today announced that ... key clinical trials of aldoxorubicin, a pivotal global Phase ... and a global Phase 2b clinical trial in small ... Society for Medical Oncology (ESMO) 2014 Congress being held ...
Breaking Medicine Technology:Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 2Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference 3Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
Designed for simple operation, the Model 515B pulse oximeter is ideal for use in any clinical setting; from emergency hospital transport to continuous monitoring in Anesthesia, Intensive Care and Gen...
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... Nellcor NPB-290 and NPB-295 Pulse Oximeters ... provide accuracy, reliability and proven signal ... poorly perfused patients. Equipped with Oxismart ... Technology, these pulse oximeters identify electronic ...
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
Medicine Products: